TOULOUSE, France & ANN ARBOR, Mich.--(BUSINESS WIRE)--Cerenis Therapeutics (‘Cerenis’), a biopharmaceutical company developing novel high-density lipoprotein (‘HDL’) therapies for the treatment of cardiovascular and metabolic diseases, today announced the appointment of John F. Paolini, MD, PhD, FACC as Chief Medical Officer.
